NRICM101 (Qinguan No.1) and NRICM201 (Qinguan No.2) are Taiwanese government-approved TCM formulae for mild-to-moderate and severe COVID-19, respectively. This paper constructs a unified disease-phase geometric pharmacology framework that repositions NRICM101 as an early viral-phase formula (Phase I-III: viral entry suppression, replication inhibition, innate immune priming) and NRICM201 as a severe host-dysregulation formula (Phase IV-VII: cytokine storm attenuation, oxidative/mitochondrial rescue, vascular barrier protection, multi-organ preservation). Key contributions: (1) Disease-phase mapping of NRICM101 Jun/Chen/Zuo clusters: Jun=Mpro inhibition (Phase II), Chen=multi-target L=5 flavonoid adaptors (Phase I-III), Zuo=ACE2/anti-inflammatory support (Phase I + early III). (2) NRICM101 broad-spectrum activity against influenza A and RSV is interpreted as coverage of a shared host pathological phase space (NF-kB/IFN imbalance, oxidative stress, innate immune activation), not virus-specific targeting. (3) NRICM201 cross-disease efficacy in COPD, viral-induced MOF, and toxin-induced MOF (author animal experimental data) is interpreted as rescue from a convergent pathological inflammatory attractor. (4) Lo-Shu geometric zone analysis: NRICM101 operates in L=4-5 multi-target Yin-center zone; NRICM201 expands coverage to L=2/4 defensive zones. The two formulae represent a pharmacological phase transition, not a dose escalation.
Yao-Kai Kao (Tue,) studied this question.